Expert Interview

This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

A Third Opinion: Discussing the FDA warning label for Horizon's Tepezza for TED and how severe hearing-related side effects may alter prescribing patterns

Ticker(s): HZNP

Who's the expert?

Institution: Self-Employed

Board-certified ophthalmologist and award-winning retinal specialist, Medical Director for the Macular Degeneration Association (MDA) and Founder & CEO of Mali Enterprises
manages 2,000 patients with GA and utilizes the most advanced surgical techniques and technology in the world to deliver the highest quality retinal surgery for his patients
Interested in new treatments for wet macular degeneration, diabetic retinopathy, and uveitis.

Interview Goal

On this call we will be digging in to the FDA's new warning and precaution regarding the potential for severe hearing related side effects added to the label of Horizon’s blockbuster monoclonal antibody Tepezza (teprotumumab-trbw), which is used as a treatment for TED and how that may effect prescribing patterns for this medication.

Do you want answers to these questions?

Yes! Sign me up for FREE
so I can learn more Yes.
LOGIN!

Click Here to Access
This Project

Slingshot Insights Explained

JOIN FOR FREE TODAY

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.

Reason

Click Here to Access
This Project

*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.